Answers are grounded in this paper and cite their sources.
Randomized trial explores HJC0152's ability to enhance immunotherapy in TNBC, indicating promising therapeutic potential.
Objectives/Goals: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies. This study explores whether the Niclosamide derivative HJC0152 can act as an immune modulator to reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy efficacy. Methods/Study Population: Niclosamide-derived HJC0152 was developed as a novel cancer therapeutic and immunomodulating agent. Human and murine TNBC cell lines, as well as primary mouse MDSC cells, were treated with HJC0152. PD-L1 expression in TNBC cells and key immunosuppressive markers in MDSCs (Arg1, Arg2, and iNOS) were evaluated. The immunosuppressive function of MDSCs was further assessed using a T cell co-culture assay. In vivo studies are planned to assess the therapeutic efficacy of HJC0152 in combination with anti-PD-1 therapy using syngeneic TNBC mouse models. Results/Anticipated Results: HJC0152 exhibits improved solubility compared to Niclosamide and displays potent anticancer activity both in vitro and in vivo . RNA-Seq analysis of human TNBC cells treated with HJC0152 revealed significant downregulation of PD-L1 gene expression, which was further validated at the protein level by Western blot analysis. In addition, HJC0152 suppressed Arg1 expression in mouse MDSCs, a key mediator of immunosuppressive myeloid cell function. Together, PD-L1 and Arg1 pathways represent critical mechanisms of tumor immune evasion, and our findings highlight HJC0152 as a promising immune modulatory agent capable of enhancing the efficacy of immune checkpoint blockade in TNBC. Discussion/Significance of Impact: This study presents a novel immunotherapy strategy for TNBC using HJC0152, which downregulates tumor-derived PD-L1 and inhibits Arg1 signaling in MDSCs. As the first investigation of HJC0152 combined with anti-PD-1 in TNBC models, it may support future clinical trials and offer a new therapeutic option for TNBC patients.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: